Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study
作者： Giuseppe Di Lorenzo , Antonio Rea , Chiara Carlomagno , Stefano Pepe , Giovannella Palmieri
关键词:
摘要: AIM: To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase II study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA). METHODS: Thirty-one patients hystologically-confirmed, inoperable HCC, received combination chemotherapy PLD 25 mg/mq on d 1, 5FU 1200 48 h continuous infusion, oral FA 30 mg 1 2 every 3 wk until disease progression or intolerable toxicity. RESULTS: The median age was 65 years (range 41-82) 28 were hepatitis C virus seropositive (90%). majority Child-Pugh Class B (55%). Two showed partial response (PR), 16 had stable (SD). With follow-up 14 mo, time to all evaluable 4 mo (95% CI 1.7-7). Median overall survival 9 3-24 mo). After year, 18 PR/SD alive. Chemotherapy well tolerated. CONCLUSION: PLD/FU/FA seems capable achieving durable stabilization HCC. manageable toxicity supports role for other anticancer agents.
core.ac.uk
unisa.it参考文章(27)
Ugochukwu C. Nzeako, Zachary D. Goodman, Kamal G. Ishak, Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Livers: A Clinico-Histopathologic Study of 804 North American Patients American Journal of Clinical Pathology. ,vol. 105, pp. 65- 75 ,(1996) , 10.1093/AJCP/105.1.65
Se Hoon Park, Yuna Lee, Sang Hoon Han, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Yeon Ho Park, Jeong Nam Lee, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, None, Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma BMC Cancer. ,vol. 6, pp. 3- 3 ,(2006) , 10.1186/1471-2407-6-3
Ruey-Long Hong, Yun-Long Tseng, A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma Cancer Chemotherapy and Pharmacology. ,vol. 51, pp. 433- 438 ,(2003) , 10.1007/S00280-003-0583-2
B Uziely, S Jeffers, R Isacson, K Kutsch, D Wei-Tsao, Z Yehoshua, E Libson, F M Muggia, A Gabizon, Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. Journal of Clinical Oncology. ,vol. 13, pp. 1777- 1785 ,(1995) , 10.1200/JCO.1995.13.7.1777
A. Gabizon, F. Martin, Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin Rationale for Use in Solid Tumours Drugs. ,vol. 54, pp. 15- 21 ,(1997) , 10.2165/00003495-199700544-00005
U. Halm, G. Etzrodt, I. Schiefke, F. Schmidt, H. Witzigmann, J. Mössner, F. Berr, A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma Annals of Oncology. ,vol. 11, pp. 113- 114 ,(2000) , 10.1023/A:1008386822906
Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui‐Chee Wu, Gerald Chee‐Bunn Chan, Hsiang‐Ju Lin, None, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. ,vol. 62, pp. 479- 483 ,(1988) , 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
J W Valle, A Dangoor, J Beech, D J Sherlock, S M Lee, J H Scarffe, R Swindell, M Ranson, Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study British Journal of Cancer. ,vol. 92, pp. 628- 630 ,(2005) , 10.1038/SJ.BJC.6602394
Say-Bee Poh, Li-Yuan Bai, Po-Min Chen, Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. American Journal of Clinical Oncology. ,vol. 28, pp. 540- 546 ,(2005) , 10.1097/01.COC.0000177911.36579.3D
G ABOUALFA, Hepatocellular Carcinoma: Molecular Biology and Therapy Seminars in Oncology. ,vol. 33, pp. 79- 83 ,(2006) , 10.1053/J.SEMINONCOL.2006.10.015